Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
Our top-notch dedicated system is used to design specialised libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
The procedure entails thorough molecular simulations of the catalytic and allosteric binding pockets, accompanied by ensemble virtual screening that factors in their conformational flexibility. When developing modulators, the structural modifications brought about by reaction intermediates are factored in to optimize activity and selectivity.
Our library is unique due to several crucial aspects:
partner
Reaxense
upacc
Q8NBI2
UPID:
CYAC3_HUMAN
Alternative names:
Cytochrome b ascorbate-dependent protein 3; Cytochrome b561 family member A3; Lysosomal cytochrome b
Alternative UPACC:
Q8NBI2; B3KPU2; B4DLN9; J3KQH4; Q6PK96
Background:
Lysosomal membrane ascorbate-dependent ferrireductase CYB561A3, also known as Cytochrome b ascorbate-dependent protein 3, plays a crucial role in cellular iron homeostasis. It functions as a transmembrane reductase, utilizing ascorbate to transfer electrons across membranes, thereby reducing iron cations Fe(3+) to Fe(2+) within the lumen of the late endosome and lysosome. This process facilitates the extrusion of reduced iron to the cytoplasm, essential for various cellular functions.
Therapeutic significance:
Understanding the role of Lysosomal membrane ascorbate-dependent ferrireductase CYB561A3 could open doors to potential therapeutic strategies.